Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

被引:17
|
作者
Gharavi, Robert [1 ,2 ]
Hedrich, William [1 ]
Wang, Hongbing [1 ]
Hassan, Hazem E. [1 ,3 ]
机构
[1] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201 USA
[2] MedImmune, Clin Dev, Gaithersburg, MD 20878 USA
[3] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
关键词
opioid abuse; opioid DDI; opioid drug transporters; opioids and P-gp; BLOOD-BRAIN-BARRIER; ORGANIC CATION TRANSPORTERS; P-GLYCOPROTEIN EXPRESSION; LONG QT SYNDROME; IN-VITRO; GENETIC POLYMORPHISMS; METHADONE PHARMACOKINETICS; MORPHINE PHARMACOKINETICS; CYTOCHROME P4503A; RENAL CLEARANCE;
D O I
10.1007/s11095-015-1711-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Opioid-related deaths, abuse, and drug interactions are growing epidemic problems that have medical, social, and economic implications. Drug transporters play a major role in the disposition of many drugs, including opioids; hence they can modulate their pharmacokinetics, pharmacodynamics and their associated drug-drug interactions (DDIs). Our understanding of the interaction of transporters with many therapeutic agents is improving; however, investigating such interactions with opioids is progressing relatively slowly despite the alarming number of opioids-mediated DDIs that may be related to transporters. This review presents a comprehensive report of the current literature relating to opioids and their drug transporter interactions. Additionally, it highlights the emergence of transporters that are yet to be fully identified but may play prominent roles in the disposition of opioids, the growing interest in transporter genomics for opioids, and the potential implications of opioid-drug transporter interactions for cancer treatments. A better understanding of drug transporters interactions with opioids will provide greater insight into potential clinical DDIs and could help improve opioids safety and efficacy.
引用
收藏
页码:2477 / 2502
页数:26
相关论文
共 50 条
  • [1] Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions
    Robert Gharavi
    William Hedrich
    Hongbing Wang
    Hazem E. Hassan
    Pharmaceutical Research, 2015, 32 : 2477 - 2502
  • [2] Transporter-mediated drug interactions:: clinical implications and in vitro assessment
    Lin, Jiunn H.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (01) : 81 - 92
  • [3] Clinical Aspects of Transporter-Mediated Drug-Drug Interactions
    Gessner, Arne
    Koenig, Joerg
    Fromm, Martin F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1386 - 1394
  • [4] Transporter-mediated drug-drug interactions
    Mueller, Fabian
    Fromm, Martin F.
    PHARMACOGENOMICS, 2011, 12 (07) : 1017 - 1037
  • [5] Transporter-mediated drug-drug interactions
    Shitara, Yoshihisa
    DRUG METABOLISM REVIEWS, 2006, 38 : 12 - 13
  • [6] Predicting Transporter-mediated Drug Interactions
    Zhang, L.
    Sparreboom, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (04) : 447 - 449
  • [7] Transporter-Mediated Drug-Drug Interactions
    Zhang, L.
    Huang, S-M
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 481 - 484
  • [8] PREDICTION OF RENAL TRANSPORTER-MEDIATED CLINICAL DRUG-DRUG INTERACTIONS
    Feng, Bo
    Lu, Yasong
    Varma, Manthena
    Rotter, Charles J.
    DRUG METABOLISM REVIEWS, 2014, 45 : 253 - 254
  • [9] Molecular properties associated with transporter-mediated drug disposition
    Varma, Manthena V.
    Lai, Yurong
    El-Kattan, Ayman F.
    ADVANCED DRUG DELIVERY REVIEWS, 2017, 116 : 92 - 99
  • [10] Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
    Manthena V. S. Varma
    Yurong Lai
    Bo Feng
    John Litchfield
    Theunis C. Goosen
    Arthur Bergman
    Pharmaceutical Research, 2012, 29 : 2860 - 2873